Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Short Interest Down 86.5% in August

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) was the target of a large decrease in short interest during the month of August. As of August 14th, there was short interest totaling 187 shares, a decrease of 86.5% from the July 30th total of 1,385 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average daily trading volume, of 1,011 shares, the short-interest ratio is currently 0.2 days.

Institutional Investors Weigh In On Molecular Partners

A hedge fund recently bought a new position in Molecular Partners stock. SmartHarvest Portfolios LLC bought a new stake in Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 12,311 shares of the company’s stock, valued at approximately $54,000. Hedge funds and other institutional investors own 26.55% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. HC Wainwright reiterated a “buy” rating on shares of Molecular Partners in a report on Monday, July 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Molecular Partners in a report on Wednesday, July 8th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Molecular Partners currently has an average rating of “Hold” and an average price target of $8.38.

Molecular Partners Stock Performance

Shares of NASDAQ:MOLN traded up $0.16 during midday trading on Thursday, hitting $4.61. 4,720 shares of the company’s stock traded hands, compared to its average volume of 4,826. The firm’s fifty day moving average price is $4.05 and its two-hundred day moving average price is $4.23. Molecular Partners has a twelve month low of $3.53 and a twelve month high of $5.36. The company has a market cap of $186.19 million, a PE ratio of -2.38 and a beta of 1.08.

Molecular Partners Company Profile

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company’s development pipeline spans infectious diseases, ophthalmology and oncology.